Table 2 Association of pathologic features of aggressiveness with body mass index⩾30 (vs <25) after multivariable adjustment for patient age and pre-operative PSA
Pathologic feature | Mayo Rochester (N=3061) | Mayo Florida (N=339) | ||
|---|---|---|---|---|
OR (95% CI) | P-value | OR (95% CI) | P-value | |
Prostatic volume (cm3) doubling | 1.49 (1.33–1.68) | <0.0001 | 1.43 (0.94, 2.18) | 0.099 |
Tumor volume (cm3) doubling | 1.06 (1.03–1.09) | <0.0001 | 1.17 (0.95, 1.43) | 0.14 |
Pathologic T stage a | ||||
pT2 | REF | — | REF | — |
pT3, pT4, pTxN+ | 1.30 (1.05–1.62) | 0.02 | 1.45 (0.65–3.23) | 0.36 |
Pathologic Gleason score | ||||
5–6 | REF | — | REF | — |
7 | 1.36 (1.17–1.60) | <0.001 | 1.01 (0.62–1.64) | 0.96 |
8–10 | 1.50 (1.14–1.96) | 0.003 | 1.42 (0.55–3.66) | 0.47 |
Positive margin | ||||
No | REF | — | REF | — |
Yes | 1.56 (1.30–1.89) | <0.001 | 1.61 (0.95–2.71) | 0.077 |
Seminal vesicle involvement | ||||
No | REF | — | REF | — |
Yes | 1.41 (1.03–1.92) | 0.0311 | 3.72 (1.05–13.2) | 0.042 |
Extra-capsular extension | ||||
No | REF | — | REF | — |
Yes | 1.26 (1.01–1.57) | 0.045 | 1.37 (0.77–2.46) | 0.28 |
